GGrantIndex
← Leaderboards

Lori Sakoda

Kaiser Foundation Research Institute

$4,805,191
Attributed
$8,807,974
Total exposure
6
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.8M · FY201525
$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$8,807,974 · 6

By mechanism

R01$5,554,245 · 4
UG1$2,333,610 · 1
K07$920,119 · 1

Most similar at Kaiser Foundation Research Institute

Same institution · by research overlap

Others in their field

Top investigators on “Follow-Up

Research focus

Follow-UpEnrollmentAdultDiagnosisMalignant Neoplasm Of LungRaceScreening For CancerScreeningElectronic Health RecordCaliforniaEligibility DeterminationMortalitySurveysSmokingMalignant NeoplasmsRecording Of Previous EventsResourcesSmoking HistoryEarly DiagnosisCohortSmoking CessationRecommendationCancer DetectionTumor

Grant awards (17)

OPTimizing surveillance in lung cancer survivors with novel IMAging biomarkers and deep-Learning (OPTIMAL)$968,999
R01 · FY2025 · CA
Multi-Cancer Early Detection and Screening (MED SCREEN) Study$894,340
UG1 · FY2025 · CA
A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors$766,294
R01 · FY2025 · CA
Vanguard Study Administrative Supplement$581,000
UG1 · FY2025 · CA
Multilevel Determinants of Differences in Lung Cancer Screening Utilization$549,580
R01 · FY2025 · CA · contact PI
Multi-Ethnic Multi-Cancer Early Detection and Screening (MED SCREEN) Study$858,270
UG1 · FY2024 · CA
A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors$735,428
R01 · FY2024 · CA
Multilevel Determinants of Racial/Ethnic Disparities in Lung Cancer Screening Utilization$8,149
R01 · FY2024 · CA · contact PI
A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors$815,928
R01 · FY2023 · CA
Multilevel Determinants of Racial/Ethnic Disparities in Lung Cancer Screening Utilization$536,775
R01 · FY2023 · CA · contact PI
Multilevel Determinants of Racial/Ethnic Disparities in Lung Cancer Screening Utilization$643,926
R01 · FY2022 · CA · contact PI
Genome-wide Pleiotropy Scan across Multiple Cancers$529,166
R01 · FY2019 · CA
Evaluating a Risk Prediction Model for Lung Cancer$149,359
K07 · FY2019 · CA · contact PI
Evaluating a Risk Prediction Model for Lung Cancer$192,864
K07 · FY2018 · CA · contact PI
Evaluating a Risk Prediction Model for Lung Cancer$192,744
K07 · FY2017 · CA · contact PI
Evaluating a Risk Prediction Model for Lung Cancer$192,384
K07 · FY2016 · CA · contact PI
Evaluating a Risk Prediction Model for Lung Cancer$192,768
K07 · FY2015 · CA · contact PI